THRX Stock Overview
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients.
Theseus Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.34|
|52 Week High||US$24.54|
|52 Week Low||US$4.86|
|1 Month Change||21.40%|
|3 Month Change||13.47%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-55.11%|
Recent News & Updates
Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line
Theseus Pharmaceuticals press release (NASDAQ:THRX): Q2 GAAP EPS of -$0.30 in-line. Cash and cash equivalents and short-term and long-term investments of $228.6 million.
|THRX||US Pharmaceuticals||US Market|
Return vs Industry: Insufficient data to determine how THRX performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how THRX performed against the US Market.
|THRX Average Weekly Movement||11.7%|
|Pharmaceuticals Industry Average Movement||12.0%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: THRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: THRX's weekly volatility (12%) has been stable over the past year.
About the Company
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.
Theseus Pharmaceuticals Fundamentals Summary
|THRX fundamental statistics|
Is THRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|THRX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.00|
|Net Profit Margin||0.00%|
How did THRX perform over the long term?See historical performance and comparison
Is THRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for THRX?
Other financial metrics that can be useful for relative valuation.
|What is THRX's n/a Ratio?|
Price to Book Ratio vs Peers
How does THRX's PB Ratio compare to its peers?
|THRX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
WVE Wave Life Sciences
MNMD Mind Medicine (MindMed)
CBAY CymaBay Therapeutics
THRX Theseus Pharmaceuticals
Price-To-Book vs Peers: THRX is good value based on its Price-To-Book Ratio (1.4x) compared to the peer average (11.1x).
Price to Earnings Ratio vs Industry
How does THRX's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: THRX is good value based on its Price-To-Book Ratio (1.4x) compared to the US Pharmaceuticals industry average (2.1x)
Price to Book Ratio vs Fair Ratio
What is THRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||1.4x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate THRX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of THRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate THRX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate THRX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Theseus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: THRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: THRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: THRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: THRX is forecast to have no revenue next year.
High Growth Revenue: THRX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if THRX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Theseus Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: THRX is currently unprofitable.
Growing Profit Margin: THRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if THRX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare THRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: THRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).
Return on Equity
High ROE: THRX has a negative Return on Equity (-16.67%), as it is currently unprofitable.
Discover strong past performing companies
How is Theseus Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: THRX's short term assets ($227.5M) exceed its short term liabilities ($5.2M).
Long Term Liabilities: THRX's short term assets ($227.5M) exceed its long term liabilities ($4.1M).
Debt to Equity History and Analysis
Debt Level: THRX is debt free.
Reducing Debt: THRX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: THRX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: THRX has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 72% each year.
Discover healthy companies
What is Theseus Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate THRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate THRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if THRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if THRX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as THRX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tim Clackson (57 yo)
Dr. Timothy P. Clackson, also known as Tim, Ph D., is a Director at Elevation Oncology, Inc. since May 2020. Dr. Clackson serves as the Chief Executive Officer and President at Theseus Pharmaceuticals, Inc...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD7.09M) is above average for companies of similar size in the US market ($USD2.53M).
Compensation vs Earnings: Insufficient data to compare Tim's compensation with company performance.
Experienced Management: THRX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: THRX's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: THRX only recently listed within the past 12 months.
Theseus Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Theseus Pharmaceuticals, Inc.
- Ticker: THRX
- Exchange: NasdaqGS
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$318.214m
- Shares outstanding: 38.16m
- Website: https://theseusrx.com
Number of Employees
- Theseus Pharmaceuticals, Inc.
- 245 Main Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/16 00:00|
|End of Day Share Price||2022/08/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.